IHC analysis with antibodies against DEK and CD138 was performed on the FFPE samples of MM and monoclonal gammapathies of uncertain significance (MGUS) patients, the latter of whom carry a risk of progression to symptomatic MM of approximately 1% per year. Here, SDC1 is linked to Miyoshi myopathy.